Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 18/20 | 0.68 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1406006 | 0.99 | GSK3B (0.67) | GSK3BCDK2CDK16DYRK1AHTR2A | |
| SCHEMBL19101740 | 0.91 | GSK3B (0.68) | GSK3BCDK2CDK16DYRK1AHTR2A | |
| SCHEMBL1405918 | 0.87 | GSK3B (0.72) | GSK3BCDK2CDK16DYRK1AHTR2A | |
| Hydrochloric Acid SCHEMBL1405699 | 0.87 | GSK3B (0.71) | GSK3BCDK2CDK16DYRK1AHTR2A | |
| SCHEMBL6952214 | 0.82 | GSK3B (0.62) | GSK3BHTR2A | |
| SCHEMBL16321074 | 0.82 | GSK3B (0.75) | GSK3BHTR4 | |
| SCHEMBL6957369 | 0.82 | GSK3B (0.70) | GSK3BDYRK1A | |
| SCHEMBL16322572 | 0.81 | GSK3B (1.00) | GSK3BCDK2CDK16DYRK1A | |
| SCHEMBL30068530 | 0.80 | RAB9A (0.61) | GSK3BCDK2DYRK1AKCNH2 | |
| SCHEMBL5433264 | 0.80 | RAB9A (0.61) | GSK3BCDK2DYRK1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622892-B1 | INDAZOLES HAVING ANALGESIC ACTIVITY | ACRAF (IT) | 2011-03-09 | — | — | EP | claimed |
| US-7662836-B2 | Indazole having analgesic activity | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2010-02-16 | — | — | US | claimed |
| US-20070010555-A1 | Indazole having analgesic activity | AZIENDE CHIM. RUIN. ANGEL. FRA. A.C.R.A.F. S.P.A. (IT) | 2007-01-11 | — | — | US | claimed |
| EP-1622892-A1 | INDAZOLES HAVING ANALGESIC ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2006-02-08 | — | — | EP | claimed |
| WO-2004101548-A1 | INDAZOLE HAVING ANALGESIC ACTIVITY , | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2004-11-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010555-A1 | Indazole having analgesic activity | ACHE, CYP3A43, RPL35A | GSK3B 2637/4885CDK2 2456/4885CDK16 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.